{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:33Z","timestamp":1787009613445,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801434"],"award-info":[{"award-number":["81801434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770869"],"award-info":[{"award-number":["81770869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900636"],"award-info":[{"award-number":["81900636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31900413"],"award-info":[{"award-number":["31900413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Province Key Research and Development Program","award":["2018CXGC1207"],"award-info":[{"award-number":["2018CXGC1207"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2018ZC1053"],"award-info":[{"award-number":["ZR2018ZC1053"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 983 gout patients on fenofibrate treatment who visited the dedicated Gout Clinic at the Affiliated Hospital of Qingdao University between September 2016 and June 2020 were retrospectively enrolled from the electronic records system. Fenofibrate-associated nephrotoxicity was defined as an increase in serum creatinine (SCr) \u22650.3\u2009mg\/dl within 6\u2009months of fenofibrate initiation. The change trend of SCr and uric acid levels during the treatment period were assessed by a generalised additive mixed model (GAMM). Multivariate analysis was performed for risk factors affecting elevated SCr.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 100 (10.2%) patients experienced an increase in SCr \u22650.3\u2009mg\/dl within 6\u2009months after fenofibrate initiation. The median change of SCr in the whole cohort was 0.11\u2009mg\/dl [interquartile range (IQR) 0.03\u20130.20], whereas it was 0.36 (0.33\u20130.45) in the fenofibrate-associated nephrotoxicity group. In a multivariable regression model, chronic kidney disease (CKD) [odds ratio (OR) 2.39 (95% CI 1.48, 3.86)] and tophus [OR 2.29 (95% CI 1.39, 3.78)] were identified to be risk predictors, independent of measured covariates, of fenofibrate-associated nephrotoxicity. During the treatment period, although SCr temporarily increased, serum urate and triglyceride concentrations decreased using the interaction analysis of GAMM. Of those with fenofibrate withdrawal records, the SCr increase in 65% of patients was reversed after an average of 49\u2009days off the drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This observational study implied that fenofibrate-associated nephrotoxicity occurs frequently in gout patients, especially in patients with tophi or CKD. The potential renal risks of fenofibrate usage in gout needs additional research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab231","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T07:11:27Z","timestamp":1615187487000},"page":"5020-5027","source":"Crossref","is-referenced-by-count":9,"title":["Effects of fenofibrate therapy on renal function in primary gout patients"],"prefix":"10.1093","volume":"60","author":[{"given":"Xinde","family":"Li","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2886-8285","authenticated-orcid":false,"given":"Jie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aichang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-8726","authenticated-orcid":false,"given":"Tony R","family":"Merriman","sequence":"additional","affiliation":[{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"},{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, Alabama, USA"},{"name":"Department of Biochemistry, University of Otago, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"2021110402575676800_keab231-B1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2021110402575676800_keab231-B2","doi-asserted-by":"crossref","first-page":"762820","DOI":"10.1155\/2015\/762820","article-title":"Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis","volume":"2015","author":"Liu","year":"2015","journal-title":"Biomed Res Int"},{"key":"2021110402575676800_keab231-B3","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","article-title":"Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile","volume":"47","author":"Choi","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575676800_keab231-B4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2021110402575676800_keab231-B5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/rheumatology\/kep047","article-title":"Perceptions of disease and health-related quality of life among patients with gout","volume":"48","author":"Lee","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575676800_keab231-B6","doi-asserted-by":"crossref","first-page":"105078","DOI":"10.1016\/j.jbspin.2020.09.010","article-title":"Trends in the manifestations of 9754 gout patients in a Chinese clinical center: a 10-year observational study","author":"Gao","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2021110402575676800_keab231-B7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021110402575676800_keab231-B8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021110402575676800_keab231-B9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British Society for Rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575676800_keab231-B10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575676800_keab231-B11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2021110402575676800_keab231-B12","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1038\/s41598-018-35175-z","article-title":"Effect of fenofibrate on uric acid level in patients with gout","volume":"8","author":"Jung","year":"2018","journal-title":"Sci Rep"},{"key":"2021110402575676800_keab231-B13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3904\/kjim.2006.21.2.89","article-title":"Effect of fenofibrate in combination with urate lowering agents in patients with gout","volume":"21","author":"Lee","year":"2006","journal-title":"Korean J Intern Med"},{"key":"2021110402575676800_keab231-B14","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021110402575676800_keab231-B15","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1097\/CCM.0b013e318168e375","article-title":"An overview of drug-induced acute kidney injury","volume":"36","author":"Pannu","year":"2008","journal-title":"Crit Care Med"},{"key":"2021110402575676800_keab231-B16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2011.08.008","article-title":"Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity","volume":"6","author":"Attridge","year":"2012","journal-title":"J Clin Lipidol"},{"key":"2021110402575676800_keab231-B17","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2021110402575676800_keab231-B18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/annrheumdis-2013-204067","article-title":"Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021110402575676800_keab231-B19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021110402575676800_keab231-B20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1172\/JCI118118","article-title":"Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor","volume":"96","author":"Vu-Dac","year":"1995","journal-title":"J Clin Invest"},{"key":"2021110402575676800_keab231-B21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/s-2007-982517","article-title":"Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH","volume":"39","author":"Takahashi","year":"2007","journal-title":"Horm Metab Res"},{"key":"2021110402575676800_keab231-B22","first-page":"41","article-title":"[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]","volume":"20","author":"Hottelart","year":"1999","journal-title":"Nephrologie"},{"key":"2021110402575676800_keab231-B23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"key":"2021110402575676800_keab231-B24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.vph.2006.01.004","article-title":"Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1","volume":"44","author":"Chen","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"2021110402575676800_keab231-B25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1258\/ebm.2009.009218","article-title":"Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-\u03baB and transforming growth factor-\u03b21\/Smad3 in diabetic nephropathy","volume":"235","author":"Li","year":"2010","journal-title":"Exp Biol Med (Maywood)"},{"key":"2021110402575676800_keab231-B26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/jrms.JRMS_772_19","article-title":"Fenofibrate-induced renal dysfunction, yes or no?","volume":"25","author":"Emami","year":"2020","journal-title":"J Res Med Sci"},{"key":"2021110402575676800_keab231-B27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.00600206","article-title":"Surrogate end points for clinical trials of kidney disease progression","volume":"1","author":"Stevens","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021110402575676800_keab231-B28","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"2021110402575676800_keab231-B29","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s10067-017-3969-y","article-title":"Clinical characteristics associated with subcutaneous tophi formation in Chinese gout patients: a retrospective study","volume":"37","author":"Ma","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2021110402575676800_keab231-B30","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3899\/jrheum.131240","article-title":"Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout","volume":"41","author":"Lu","year":"2014","journal-title":"J Rheumatol"},{"key":"2021110402575676800_keab231-B31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-018-1746-1","article-title":"Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study","volume":"20","author":"Roughley","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021110402575676800_keab231-B32","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1210\/jc.2002-021973","article-title":"UROMODULIN mutations cause familial juvenile hyperuricemic nephropathy","volume":"88","author":"Turner","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2021110402575676800_keab231-B33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"2021110402575676800_keab231-B34","first-page":"2294","article-title":"Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol","volume":"28","author":"Yamamoto","year":"2001","journal-title":"J Rheumatol"},{"key":"2021110402575676800_keab231-B35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.phrs.2015.09.012","article-title":"Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"102","author":"Derosa","year":"2015","journal-title":"Pharmacol Res"},{"key":"2021110402575676800_keab231-B36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","article-title":"Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort","volume":"21","author":"Liang","year":"2019","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab231\/37011524\/keab231.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5020\/41073270\/keab231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5020\/41073270\/keab231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T23:00:51Z","timestamp":1635980451000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/5020\/6168132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,3,11]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab231","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,3,11]]}}}